BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Fulcrum Therapeutics, Inc. (Nasdaq – FULC)
Under the terms of the Merger Agreement, Fulcrum Therapeutics will be acquired by Slate Medicines, Inc. Fulcrum stockholders are expected to own 5.0% of the combined company and Slate stockholders are expected to own 95.0% of the combined company. The investigation concerns whether the Fulcrum Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/fulcrum-therapeutics-inc-nasdaq-fulc/.
Weave Communications, Inc. (NYSE – WEAV)
Under the terms of the Merger Agreement, Weave Communications will be acquired by Francisco Partners for $7.40 per share in cash in a deal with an aggregate equity valuation of approximately $650 Million. The investigation concerns whether the Weave Communications Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/weave-communications-inc-nyse-weav/.
Iridium Communications Inc. (Nasdaq – IRDM)
Under the terms of the Merger Agreement, Iridium will be acquired by Rocket Lab Corporation (Nasdaq - RKLB) for $54 per share in a cash and stock transaction, representing an enterprise value for Iridium of approximately $8.0 billion. The investigation concerns whether the Iridium Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/iridium-communications-inc-nasdaq-irdm/.
Bio-Techne Corporation (Nasdaq – TECH)
Under the terms of the Merger Agreement, Bio-Techne Corporation will be acquired by Merck KGaA for $73.00 per share in cash, representing a total enterprise value of approximately $11.3 billion. The investigation concerns whether the Bio-Techne Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/bio-techne-corporation-nasdaq-tech/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
